- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02367313
A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection (SPIRITUS)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter trial to be conducted at approximately 60 sites among 6-8 northern hemisphere countries in North America and Central Europe. Sufficient patients will be randomized in order to recruit 150 subjects who are laboratory confirmed for human rhinovirus (HRV) infection. Depending on HRV PCR positivity rates, it is expected that randomization of 250-480 subjects will be required to achieve this number of subjects with HRV infection.
Appropriate asthma subjects will be screened up to 180 days prior to presentation at the study site with symptoms of presumed HRV infection for potential study inclusion on Study Day 1. The study drug treatment period has a duration of 7 days, beginning on Study Day 1. Follow-up study visits to the clinic occur on Study Days 3, 5, 7, 14, 21, and 28 with a telephonic final safety follow-up visit conducted on Study Day 35. Thus, depending on the duration of the screening period, a subject's duration of participation can be estimated to last from approximately 37 days up to 215 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ruse, Bulgaria, 7002
- Biota Investigational Site
-
Sofia, Bulgaria, 1202
- Biota Investigational Site
-
Sofia, Bulgaria, 1407
- Biota Investigational Site
-
Sofia, Bulgaria, 1606
- Biota Investigational Site
-
Sofia, Bulgaria, 1618
- Biota Investigational Site
-
Stara Zagora, Bulgaria, 6000
- Biota Investigational Site
-
-
-
-
-
Jindrichuv Hradec, Czechia, 37701
- Biota Investigational Site
-
Kyjov, Czechia, 69733
- Biota Investigational Site
-
Lovosice, Czechia, 41002
- Biota Investigational Site
-
Melnik, Czechia, 27601
- Biota Investigational Site
-
Prague, Czechia, 18200
- Biota Investigational Site
-
Rokycany, Czechia, 33722
- Biota Investigational Site
-
-
-
-
-
Tbilisi, Georgia, 0102
- Biota Investigational Site
-
Tbilisi, Georgia, 0159
- Biota Investigational Site
-
Tbilisi, Georgia, 0186
- Biota Investigational Site
-
-
-
-
-
Bialystok, Poland, 15-044
- Biota Investigational Site
-
Kielce, Poland, 25-734
- Biota Investigational Site
-
Krakow, Poland, 31-023
- Biota Investigational Site
-
Lodz, Poland, 90-153
- Biota Investigational Site
-
Lublin, Poland, 20-552
- Biota Investigational Site
-
Skierniewice, Poland, 96-100
- Biota Investigational Site
-
Warsaw, Poland, 01-868
- Biota Investigational Site
-
Wroclaw, Poland, 50-044
- Biota Investigational Site
-
Wroclaw, Poland, 51-162
- Biota Investigational Site
-
-
-
-
-
Brasov, Romania, 500112
- Biota Investigational Site
-
Bucharest, Romania, 020671
- Biota Investigational Site
-
Craiova, Romania, 200446
- Biota Investigational Site
-
Mures, Romania, 547530
- Biota Investigational Site
-
Sibiu, Romania, 550360
- Biota Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Biota Investigational Site
-
-
Arizona
-
Flagstaff, Arizona, United States, 86001
- Biota Investigational Site
-
-
California
-
Bakersfield, California, United States, 93301
- Biota Investigational Site
-
Los Angeles, California, United States, 90025
- Biota Investigational Site
-
Orange, California, United States, 92868
- Biota Investigational Site
-
San Jose, California, United States, 95117
- Biota Investigational Site
-
Stockton, California, United States, 95207
- Biota Investigational Site
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Biota Investigational Site
-
Denver, Colorado, United States, 80230
- Biota Investigational Site
-
-
Florida
-
Hialeah, Florida, United States, 33016
- Biota Investigational Site
-
New Port Richey, Florida, United States, 34653
- Biota Investigational Site
-
Oviedo, Florida, United States, 32765
- Biota Investigational Site
-
Palmetto Bay, Florida, United States, 33157
- Biota Investigation site
-
Tallahassee, Florida, United States, 32308
- Biota Investigational Site
-
-
Idaho
-
Twin Falls, Idaho, United States, 83301
- Biota Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21236
- Biota Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Biota Investigational Site
-
-
Nebraska
-
Bellevue, Nebraska, United States, 68123
- Biota Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89146
- Biota Investigational Site
-
-
New Jersey
-
Ocean City, New Jersey, United States, 07712
- Biota Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Biota Investigational Site
-
-
New York
-
Rockville Centre, New York, United States, 11570
- Biota Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Biota Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Biota Investigational Site
-
-
Ohio
-
Middleburg, Ohio, United States, 44310
- Biota Investigational Site
-
Toledo, Ohio, United States, 43617
- Biota Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Biota Investigation site
-
-
Oregon
-
Medford, Oregon, United States, 97504
- Biota Investigational Site
-
Portland, Oregon, United States, 97202
- Biota Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Biota Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77055
- Biota Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98115
- Biota Investigational Site
-
-
Wisconsin
-
Greenfield, Wisconsin, United States, 53228
- Biota Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate and severe male and female asthma subjects aged 18 to 75 years, (inclusive)
- Established clinical history of Asthma for at least 1 year, and a history within the last 14 months (prior to screening) of asthma exacerbation due to presumed viral respiratory infections, which required asthma rescue medication treatment.
- The asthma subjects will be currently taking at least medium-dose or high-dose ICS defined as fluticasone at a dosage of at least >264 µg daily and may be taking other asthma medication preparations. The asthma subjects' medication regimen must be stable for at least 4 weeks before screening.
- Subjects will have at screening or within the last year, documented variable airway obstruction as indicated by an increase in FEV1 (>12%) to short acting bronchodilator, or positive methacholine challenge, or positive histamine challenge (PC20 <8 mg/mL).
Upon presentation to the clinic with cold symptoms, subjects will be required to be randomized and treated within 48 hours of symptom onset and will be qualified for presumptive rhinovirus infection by:
- clinical exam and the presence of each of the following Day 1 WURSS-21 symptoms at a severity of 2 or greater: runny nose, sore throat, scratchy throat.
- subjects must also have a minimum total symptom score on the Day 1 WURSS-21 of 20 points.
- subjects will be further qualified as presumptively infected with HRV via exclusion of subjects having significant fever and exclusion of subjects testing positive for influenza via Rapid Antigen Test.
Exclusion Criteria:
- Subjects presenting to the clinic with a current severe asthma exacerbation will be excluded from randomization, as well as any subject with an additional underlying respiratory medical condition other than asthma such as COPD, cystic fibrosis, or chronic sinusitis, or any other uncontrolled clinically significant disease which would interfere with the assessment outcomes or subject safety.
- Female subjects must not be pregnant or breastfeeding. Females of childbearing potential must be willing to utilize a double barrier method of contraception, as defined in this protocol, regardless of any hormonal contraception they may be concomitantly receiving.
- Male subjects must agree to use a method of birth control defined in this protocol.
- The use of medications known to moderately or severely inhibit or induce cytochrome (CYP) 3A4 and 2C19 enzymes, or those known to be sensitive substrates (with a narrow therapeutic range) of these CYPs are restricted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo twice daily
|
Active Comparator: Vapendavir 264 mg
Vapendavir 264 mg and matching placebo
|
Vapendavir 264 mg twice daily
Other Names:
Vapendavir 528 mg twice daily
Other Names:
|
Active Comparator: Vapendavir 528 mg
Vapendavir 528 mg and matching placebo
|
Vapendavir 264 mg twice daily
Other Names:
Vapendavir 528 mg twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Asthma Control Questionnaire-6 (ACQ-6)
Time Frame: Baseline (Day 1) to Study Day 14
|
Least Square (LS) mean change from baseline (Day 1) to Study Day 14 in ACQ-6 total score
|
Baseline (Day 1) to Study Day 14
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Anna Novotney-Barry, Biota Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTA798-203
- 2014-001785-95 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States